Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Fennec Pharmaceuticals Inc (FENC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/03/2025: FENC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 26.14% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 145.96M USD | Price to earnings Ratio - | 1Y Target Price 12.6 |
Price to earnings Ratio - | 1Y Target Price 12.6 | ||
Volume (30-day avg) 52279 | Beta 0.32 | 52 Weeks Range 3.96 - 11.11 | Updated Date 04/6/2025 |
52 Weeks Range 3.96 - 11.11 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-10 | When - | Estimate -0.13 | Actual -0.06 |
Profitability
Profit Margin -0.92% | Operating Margin (TTM) -11.79% |
Management Effectiveness
Return on Assets (TTM) 4.47% | Return on Equity (TTM) -1005.59% |
Valuation
Trailing PE - | Forward PE 11.93 | Enterprise Value 138664474 | Price to Sales(TTM) 3.07 |
Enterprise Value 138664474 | Price to Sales(TTM) 3.07 | ||
Enterprise Value to Revenue 2.92 | Enterprise Value to EBITDA 28.9 | Shares Outstanding 27594000 | Shares Floating 14394138 |
Shares Outstanding 27594000 | Shares Floating 14394138 | ||
Percent Insiders 16.18 | Percent Institutions 58.47 |
Analyst Ratings
Rating 4.6 | Target Price 13.6 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Fennec Pharmaceuticals Inc
Company Overview
History and Background
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for treatment-resistant cancers in children. Founded with the goal of improving outcomes for pediatric cancer patients by mitigating chemotherapy-related toxicities.
Core Business Areas
- Pharmaceutical Development: Fennec focuses on the development and commercialization of therapies that address unmet medical needs in pediatric oncology.
Leadership and Structure
Rostislav Iakovlev, Ph.D., is the Chief Executive Officer. The company operates with a functional organizational structure centered around research, development, and commercialization activities.
Top Products and Market Share
Key Offerings
- PEDMARKu00ae: PEDMARKu00ae (sodium thiosulfate) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors. While Fennec is the sole provider of this product for this indication, competitors in treating cisplatin-induced ototoxicity could include supportive care methods or alternative chemotherapy regimens.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation, regulatory approvals, and market demand for effective treatments. Pediatric oncology represents a niche area with significant unmet needs.
Positioning
Fennec is positioned as a specialty pharmaceutical company focused on addressing chemotherapy-induced toxicities in pediatric cancer patients, offering a unique product in a market with limited options.
Total Addressable Market (TAM)
The estimated TAM for reducing cisplatin-induced ototoxicity in pediatric patients can be valued at several hundred million dollars annually. Fennec's positioning with PEDMARKu00ae allows them to capture a significant portion of this market as the only approved agent. Further penetration may require additional approvals and market development.
Upturn SWOT Analysis
Strengths
- FDA Approved Product
- Sole Provider of Approved Treatment for Cisplatin-Induced Ototoxicity
- Focus on Unmet Medical Needs in Pediatric Oncology
Weaknesses
- Reliance on Single Product
- Commercialization Challenges in a Niche Market
- Relatively Small Company Size
Opportunities
- Expansion of PEDMARKu00ae Indications
- Development of New Therapies for Pediatric Cancers
- Strategic Partnerships for Commercialization
Threats
- Regulatory Challenges
- Competition from Alternative Therapies
- Pricing and Reimbursement Pressures
Competitors and Market Share
Key Competitors
- There are no direct competitors with an approved product with the exact same mechanism of action. Indirect competitors could include companies developing supportive care products (not publicly traded).
Competitive Landscape
Fennec Pharmaceuticals holds a distinct advantage as the sole provider of an approved therapy for reducing cisplatin-induced ototoxicity. Success hinges on effective market penetration and potential future competition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Need Actuals - The historical growth of the company has been marked by clinical trial success and regulatory approvals.
Future Projections: Future growth is projected to come from increased adoption of PEDMARKu00ae and the potential development of new therapies.
Recent Initiatives: Recent initiatives include commercial launch of PEDMARKu00ae and efforts to expand market access.
Summary
Fennec Pharmaceuticals is a niche pharmaceutical company focused on pediatric oncology, particularly reducing the harmful side effects of chemotherapy. With the approval of PEDMARKu00ae, the company now holds an advantageous position but remains reliant on a single product. Key areas to watch include market penetration, successful execution of commercial strategies, and how they handle potential future competition. It is a high risk/high reward stock.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The financial data is based on publicly available information and may not be comprehensive or current. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fennec Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 2001-06-05 | CEO & Director Mr. Jeffrey S. Hackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://www.fennecpharma.com |
Full time employees 32 | Website https://www.fennecpharma.com | ||
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.